![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RF Kletzien, SD Clarke and RG Ulrich
Upjohn Laboratories, Upjohn Company, Kalamazoo, Michigan 49001.
The thiazolidinediones are a class of novel antidiabetic compounds that enhance the response of target tissues to insulin. Pioglitazone, a thiazolidinedione analog, lowers blood glucose and insulin levels in rodent models of non-insulin-dependent diabetes mellitus. We have studied the effect of pioglitazone on 3T3-L1 cells, a cell line that undergoes differentiation from a preadipocyte fibroblastic morphology to that of an adipocyte. Pioglitazone treatment of preadipocytes enhanced the insulin- or insulin-like growth factor-1 (IGF-I)-regulated differentiation (monitored by the rate of lipogenesis or triglyceride accumulation), whereas treatment of the cells in the absence of insulin or IGF-I resulted in no apparent change in the cellular phenotype. Pioglitazone caused both a leftward shift and enhanced maximum response for the IGF-I-regulated differentiation of the cells, consistent with the idea that the drug enhances the sensitivity of cells to polypeptide hormones. A series of pioglitazone analogs were tested in this system, and variations in activity relative to that of the parent compound were observed. A study of the time required for the drug to exert an effect on differentiation revealed that an increased rate of lipogenesis occurred 16-24 hr after drug treatment in appropriately staged cells. An increased rate of glucose transport and increased activity of lipogenic enzymes were noted in a time frame that correlated with the change in lipogenesis. Analysis of mRNA abundance for Glut-4, lipoprotein lipase, and glucose-6-phosphate dehydrogenase showed that pioglitazone enhanced the insulin induction of these mRNA species. Thus, pioglitazone, in combination with insulin or IGF-I, appears to be exerting effects on the cellular phenotype by eliciting changes in the expression of genes that regulate metabolic pathways leading to the acquisition of the differentiated phenotype.
This article has been cited by other articles:
|
|
 |
|
  M. Noguchi, K. Hosoda, J. Fujikura, M. Fujimoto, H. Iwakura, T. Tomita, T. Ishii, N. Arai, M. Hirata, K. Ebihara, et al. Genetic and Pharmacological Inhibition of Rho-associated Kinase II Enhances Adipogenesis J. Biol. Chem., October 5, 2007; 282(40): 29574 - 29583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mody, N. Dharker, M. Bloomston, P.-S. Wang, F.-S. Chou, T. S Glickman, T. McCaffrey, Z. Yang, A. Pumfery, D. Lee, et al. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-{alpha}, CH11 and CYC202 Endocr. Relat. Cancer, June 1, 2007; 14(2): 305 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Yu, B. H. Liu, H. J. Mersmann, and S. T. Ding Porcine peroxisome proliferator-activated receptor {gamma} induces transdifferentiation of myocytes into adipocytes J Anim Sci, October 1, 2006; 84(10): 2655 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grun, H. Watanabe, Z. Zamanian, L. Maeda, K. Arima, R. Cubacha, D. M. Gardiner, J. Kanno, T. Iguchi, and B. Blumberg Endocrine-Disrupting Organotin Compounds Are Potent Inducers of Adipogenesis in Vertebrates Mol. Endocrinol., September 1, 2006; 20(9): 2141 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fujimura, C. Kimura, T. Oe, Y. Takata, H. Sakuma, I. Aramori, and S. Mutoh A Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulator with Distinct Fat Cell Regulation Properties J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 863 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Kang, B. S. Cha, H. J. Kim, H. J. Kim, S. H. Kim, K. Y. Hur, H. J. Lee, W. S. Shim, C. W. Ahn, and H. C. Lee The 11482G>A Polymorphism in the Perilipin Gene Is Associated With Weight Gain With Rosiglitazone Treatment in Type 2 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1320 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tzameli, H. Fang, M. Ollero, H. Shi, J. K. Hamm, P. Kievit, A. N. Hollenberg, and J. S. Flier Regulated Production of a Peroxisome Proliferator-activated Receptor-{gamma} Ligand during an Early Phase of Adipocyte Differentiation in 3T3-L1 Adipocytes J. Biol. Chem., August 20, 2004; 279(34): 36093 - 36102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Colca, W. G. McDonald, D. J. Waldon, J. W. Leone, J. M. Lull, C. A. Bannow, E. T. Lund, and W. R. Mathews Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E252 - E260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. McTernan, F. M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C. L. McTernan, P. M. S. Clark, S. A. Smith, A. H. Barnett, and S. Kumar Resistin and Type 2 Diabetes: Regulation of Resistin Expression by Insulin and Rosiglitazone and the Effects of Recombinant Resistin on Lipid and Glucose Metabolism in Human Differentiated Adipocytes J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6098 - 6106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rieusset, F. Touri, L. Michalik, P. Escher, B. Desvergne, E. Niesor, and W. Wahli A New Selective Peroxisome Proliferator-Activated Receptor {gamma} Antagonist with Antiobesity and Antidiabetic Activity Mol. Endocrinol., November 1, 2002; 16(11): 2628 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Gerhold, F. Liu, G. Jiang, Z. Li, J. Xu, M. Lu, J. R. Sachs, A. Bagchi, A. Fridman, D. J. Holder, et al. Gene Expression Profile of Adipocyte Differentiation and Its Regulation by Peroxisome Proliferator-Activated Receptor-{gamma} Agonists Endocrinology, June 1, 2002; 143(6): 2106 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li and M. A. Lazar Differential Gene Regulation by PPAR{gamma} Agonist and Constitutively Active PPAR{gamma}2 Mol. Endocrinol., May 1, 2002; 16(5): 1040 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Winkler, I. Friedrich, M. W Baumstark, H. Wieland, and W. Marz Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 143 - 148. [Abstract] [PDF]
|
|
|
|
|
|
U. Smith Thiazolidinedione-induced effects beyond glycaemic control The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1_suppl): S24 - S27. [Abstract] [PDF]
|
|
|
|
|
|
B. Staels The clinical significance of PPAR{alpha} and {gamma} agonism The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1_suppl): S28 - S31. [Abstract] [PDF]
|
|
|
|
|
|
C. Nugent, J. B. Prins, J. P. Whitehead, D. Savage, J. M. Wentworth, V. K. Chatterjee, and S. O'Rahilly Potentiation of Glucose Uptake in 3T3-L1 Adipocytes by PPAR{gamma} Agonists Is Maintained in Cells Expressing a PPAR{gamma} Dominant-Negative Mutant: Evidence for Selectivity in the Downstream Responses to PPAR{gamma} Activation Mol. Endocrinol., October 1, 2001; 15(10): 1729 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Hevener, D. Reichart, A. Janez, and J. Olefsky Thiazolidinedione Treatment Prevents Free Fatty Acid-Induced Insulin Resistance in Male Wistar Rats Diabetes, October 1, 2001; 50(10): 2316 - 2322. [Abstract] [Full Text]
|
|
|
|
|
|
H. S. Camp, A. Chaudhry, and T. Leff A Novel Potent Antagonist of Peroxisome Proliferator-Activated Receptor {{gamma}} Blocks Adipocyte Differentiation But Does Not Revert the Phenotype of Terminally Differentiated Adipocytes Endocrinology, July 1, 2001; 142(7): 3207 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yang, C. Rachez, and L. P. Freedman Discrete Roles for Peroxisome Proliferator-Activated Receptor gamma and Retinoid X Receptor in Recruiting Nuclear Receptor Coactivators Mol. Cell. Biol., November 1, 2000; 20(21): 8008 - 8017. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y.-C. Kim, F. E. Gomez, B. G. Fox, and J. M. Ntambi Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes J. Lipid Res., August 1, 2000; 41(8): 1310 - 1316. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. D. Rosen, C. J. Walkey, P. Puigserver, and B. M. Spiegelman Transcriptional regulation of adipogenesis Genes & Dev., June 1, 2000; 14(11): 1293 - 1307. [Full Text]
|
|
|
|
|
|
U. Edvardsson, M. Bergström, M. Alexandersson, K. Bamberg, B. Ljung, and B. Dahllöf Rosiglitazone (BRL49653), a PPAR{gamma}-selective agonist, causes peroxisome proliferator-like liver effects in obese mice J. Lipid Res., July 1, 1999; 40(7): 1177 - 1184. [Abstract] [Full Text]
|
|
|
|
|
|
J. Berger, M. D. Leibowitz, T. W. Doebber, A. Elbrecht, B. Zhang, G. Zhou, C. Biswas, C. A. Cullinan, N. S. Hayes, Y. Li, et al. Novel Peroxisome Proliferator-activated Receptor (PPAR) gamma and PPARdelta Ligands Produce Distinct Biological Effects J. Biol. Chem., March 5, 1999; 274(10): 6718 - 6725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. King, E. Hu, D. F. Harris, P. Sarraf, B. M. Spiegelman, and T. M. Roberts DEF-1, a Novel Src SH3 Binding Protein That Promotes Adipogenesis in Fibroblastic Cell Lines Mol. Cell. Biol., March 1, 1999; 19(3): 2330 - 2337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Reginato, S. T. Bailey, S. L. Krakow, C. Minami, S. Ishii, H. Tanaka, and M. A. Lazar A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor gamma -activating Properties J. Biol. Chem., December 4, 1998; 273(49): 32679 - 32684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Thuillier, R. Baillie, X. Sha, and S. D. Clarke Cytosolic and nuclear distribution of PPAR{gamma}2 in differentiating 3T3-L1 preadipocytes J. Lipid Res., December 1, 1998; 39(12): 2329 - 2338. [Abstract] [Full Text]
|
|
|
|
|
|
S. Gasic, Y. Bodenburg, M. Nagamani, A. Green, and R. J. Urban Troglitazone Inhibits Progesterone Production in Porcine Granulosa Cells Endocrinology, December 1, 1998; 139(12): 4962 - 4966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Zierath, J. W. Ryder, T. Doebber, J. Woods, M. Wu, J. Ventre, Z. Li, C. McCrary, J. Berger, B. Zhang, et al. Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer (PPAR{gamma} Agonist) Action Endocrinology, December 1, 1998; 139(12): 5034 - 5041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Liu, H. Tanaka, S. Ishii, and J. Eckel The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes Endocrinology, November 1, 1998; 139(11): 4531 - 4539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ranganathan and P. A. Kern Thiazolidinediones Inhibit Lipoprotein Lipase Activity in Adipocytes J. Biol. Chem., October 2, 1998; 273(40): 26117 - 26122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Baillie, X. Sha, P. Thuillier, and S. D. Clarke A novel 3T3-L1 preadipocyte variant that expresses PPAR{gamma}2 and RXR{alpha} but does not undergo differentiation J. Lipid Res., October 1, 1998; 39(10): 2048 - 2053. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. M. GREGOIRE, C. M. SMAS, and H. S. SUL Understanding Adipocyte Differentiation Physiol Rev, July 1, 1998; 78(3): 783 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Young, D. R. Buckle, B. C. C. Cantello, H. Chapman, J. C. Clapham, P. J. Coyle, D. Haigh, R. M. Hindley, J. C. Holder, H. Kallender, et al. Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor gamma J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 751 - 759. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Reginato, S. L. Krakow, S. T. Bailey, and M. A. Lazar Prostaglandins Promote and Block Adipogenesis through Opposing Effects on Peroxisome Proliferator-activated Receptor gamma J. Biol. Chem., January 23, 1998; 273(4): 1855 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Martin, K. Schoonjans, A.-M. Lefebvre, B. Staels, and J. Auwerx Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARalpha and PPARgamma Activators J. Biol. Chem., November 7, 1997; 272(45): 28210 - 28217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J.-C. Fruchart, C. Fievet, J. Auwerx, and B. Staels Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1756 - 1764. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer Peroxisome Proliferator-activated Receptors alpha and gamma Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs J. Biol. Chem., February 7, 1997; 272(6): 3406 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Zilberfarb, F Pietri-Rouxel, R Jockers, S Krief, C Delouis, T Issad, and A. Strosberg Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis J. Cell Sci., January 4, 1997; 110(7): 801 - 807. [Abstract] [PDF]
|
|
|
|
|
|
B. Zhang, M. P. Graziano, T. W. Doebber, M. D. Leibowitz, S. White-Carrington, D. M. Szalkowski, P. J. Hey, M. Wu, C. A. Cullinan, P. Bailey, et al. Down-regulation of the Expression of the Obese Gene by an Antidiabetic Thiazolidinedione in Zucker Diabetic Fatty Rats and db/db Mice J. Biol. Chem., April 19, 1996; 271(16): 9455 - 9459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Teboul, D. Gaillard, L. Staccini, H. Inadera, E.-Z. Amri, and P. A. Grimaldi Thiazolidinediones and Fatty Acids Convert Myogenic Cells into Adipose-like Cells J. Biol. Chem., November 24, 1995; 270(47): 28183 - 28187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yu, W. Bayona, C. B. Kallen, H. P. Harding, C. P. Ravera, G. McMahon, M. Brown, and M. A. Lazar Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids J. Biol. Chem., October 13, 1995; 270(41): 23975 - 23983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Jür. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor [IMAGE] (PPAR[IMAGE]) J. Biol. Chem., June 2, 1995; 270(22): 12953 - 12956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. B. Reusch and D. J. Klemm Inhibition of cAMP-response Element-binding Protein Activity Decreases Protein Kinase B/Akt Expression in 3T3-L1 Adipocytes and Induces Apoptosis J. Biol. Chem., January 4, 2002; 277(2): 1426 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Rosen and B. M. Spiegelman PPARgamma : a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth J. Biol. Chem., October 5, 2001; 276(41): 37731 - 37734. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
